Raymond James reiterates Strong Buy on Profound Medical stock, $11 target
Raymond James reiterated a Strong Buy rating on Profound Medical (NASDAQ:PROF) with a $11.00 target, citing strong revenue growth and financial health. The company reported 61% revenue growth over the last year and expects $25.1M in 2026 revenue. Profound Medical also appointed Richard Fabian as President to scale sales and logistics.
How this was made
The 30-second read
Why it matters
The reiteration may attract short‑term buying but lacks fresh material.
Market read
Modest relevance for traders focused on small‑cap biotech; the rating could generate limited upside pressure.
What to watch
Potential cash burn and execution risk of scaling sales were not addressed.
Background
The article repeats an analyst's rating and target for Profound Medical, noting recent revenue growth and a new executive hire.
Ticker impact
Raymond James reiterated a Strong Buy rating on Profound Medical with a $11 price target, maintaining revenue estimates and highlighting recent revenue growth.
potential upside pressure toward the $11 target as investors price in the strong buy rating
The reiteration of a Strong Buy and a target well above current price suggests a bullish bias, but no new earnings or catalyst beyond the rating.
Market effects
Positive rating may lift sentiment in the medical device sector.
Limited to U.S. small‑cap biotech investors.
Minimal global impact.
Counterpoint
The rating may be premature given the company's modest scale and reliance on timing of sales.
Key entities
- companyProfound Medical Corp.
Medical device company focused on prostate cancer treatment.
- analystRaymond James
Equity research firm issuing the Strong Buy rating.
